• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact
  • English
  • Spanish

European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet

Inicio » EU News » Health » Farmaceutical » European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet

22 de November de 2021

The European Medicines Agency (EMA) gives the green light to the use of the anticovid pill that halves the risk of death and hospitalisation. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has endorsed the use of Merk and Ridgeback’s ‘Lagevrio’ (molnupiravir) to treat Covid-19. With this approval, Merk takes the lead in the race for an effective Covid pill.

The EMA statement commented: “The medicine, which is currently not authorised in the EU, can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19. This medicine should be given as soon as possible after diagnosis of COVID-19 and within 5 days of the onset of symptoms. The medicine, which is available in capsules, should be taken twice daily for 5 days!

The EMA has issued this advice to support national authorities who may decide on the possible early use of the medicine prior to marketing authorisation, e.g. in emergency use situations, in light of the increasing rates of infection and deaths due to COVID-19 across the EU.

One month after patients started the five-day treatment, 7.3% of patients taking molnupiravir compared to 14.1% taking placebo had been hospitalised. None died from the pill; eight patients in the placebo group did.

In terms of safety, the most common side effects reported during treatment and in the 14 days following the last dose of Lagevrio were diarrhoea, nausea, dizziness and headache, all of which were mild to moderate.

Pfizer’s antiviral under review

The EMA’s proposed conditions of use are published on its website. In addition to this new announcement, the EMA has officially communicated the review of existing data on the use of Pfizer’s new antiviral against Covid-19.

The CHMP will analyse a study comparing Pfizer’s Paxlovid with placebo in non-hospitalised patients at high risk of severe disease from Covid.

“This current review will provide recommendations for the European Union in the shortest possible time so that they can be used by national authorities wishing to make evidence-based decisions on the early use of the medicine,” the EMA said of a more comprehensive review before marketing authorisation.

Pfizer is confident that the EMA will soon approve its drug.

More information:

European Medicines Agency (EMA)

Publicaciones relacionadas:

EMA clears Pfizer’s third dose for the general adult population Commission lists key steps for effective vaccination strategies and vaccines deployment European Commission authorises second safe and effective vaccine against COVID-19 EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca EU urges AstraZeneca to explain vaccine delivery delays

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas


EMA clears Pfizer’s third dose for the general adult population


Commission lists key steps for effective vaccination strategies and vaccines deployment


European Commission authorises second safe and effective vaccine against COVID-19


EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca


EU urges AstraZeneca to explain vaccine delivery delays

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. ajustes</p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información